A study by Rahman et al. [38] indicated that guselkumab was more effective than TNF inhibitors in treating psoriatic skin, while showing comparable effectiveness in managing bronchitis, bunion, and PsA-related arthritis. This evidence concerns the gene TNF and arthritic joint disease.